Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S.
Ganan-Gomez I, et al. Among authors: ingram jp.
Nat Med. 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. Epub 2022 Mar 3.
Nat Med. 2022.
PMID: 35241842
Free PMC article.